Longevity radar — September 22, 2026: Spain rethinks pension sustainability, Alzheimer’s moves towards earlier diagnosis and treatment, and preserving independence becomes an industry

The most relevant developments on Tuesday, September 22, 2026 show the Longevity Economy moving into a new phase. Spain is quantifying the relationship between lifespan, retirement age and pension sustainability; two newly authorized Alzheimer’s blood tests are reducing diagnostic barriers in the US; an Asian biotech is launching a global Phase II trial using a biological pathway beyond amyloid; new research connects p-tau217, sleep and cognition in people developing epilepsy after 55; fall prevention is moving to the centre of healthy-ageing strategy; and menopause is increasingly becoming a public-policy, workplace and talent-retention issue.

Spain puts longer lives back into the pension equation

A new Fedea study based on European Commission Ageing Report data concludes that recent reforms improve the structural sustainability of Spain’s pension system through 2050, although the authors caution that some assumptions may be overly optimistic and that population ageing will continue to create annual financing pressure. Its sustainability indicator moves from 1.34 in 2022 to 0.90 in 2050, the strongest improvement among the five countries examined.

The underlying adjustment is substantial. Spain’s initial pension replacement rate is projected to decline from 77.2% of final salary to 64.6%, while effective retirement age rises from 64 to 66.4 and average contribution careers lengthen by approximately 2.6 years. Pension-system revenue is projected to increase by about 1.7 percentage points of GDP.

The broader consequence is the emergence of Financial Longevity as an economic category: flexible retirement, part-time work beyond 65, supplementary savings, decumulation products, long-term-care insurance and professional careers designed around longer lives.

Alzheimer’s blood tests begin becoming diagnostic infrastructure

JAMA reports that the FDA has authorized two additional Alzheimer’s blood tests, taking the number available in the US to four. Roche’s Elecsys pTau217 can support evaluation in people aged 55+ with cognitive symptoms or complaints. In the supporting study, its results agreed with PET findings in roughly 88% of cognitively impaired patients and 91% of those without cognitive impairment.

PrecivityAD2 can be used in symptomatic adults aged 40 and older. In its supporting study, the test correctly identified 98% of people with positive PET or cerebrospinal-fluid biomarkers and confirmed 93% of negative findings. These tests are not stand-alone diagnoses or population-wide screening tools for healthy people.

The business implication is substantial. Blood testing can potentially move part of Alzheimer’s assessment out of specialist centres and into existing laboratory and primary-care infrastructure, creating a pathway from detection to stratification, specialist confirmation, treatment and monitoring.

A Taiwanese biotech launches a global Phase II Alzheimer’s trial targeting cellular protein clearance

Merry Life Biomedical announced today that TML-6 is advancing into a global Phase II study involving approximately 210 people with early Alzheimer’s disease across 20 sites in Taiwan, Sweden and the US. Participants will receive 100 mg, 200 mg or placebo for 52 weeks, with Clinical Dementia Rating–Sum of Boxes as the primary endpoint and p-tau217, amyloid, GFAP and NfL among the biomarker endpoints.

The approach is noteworthy because TML-6 is being investigated through the autophagy–lysosomal pathway, the cellular machinery responsible for clearing and recycling damaged proteins and other material. The hypothesis remains unproven in patients; this trial is designed to determine whether targeting that biology can translate into clinical benefit.

The programme also illustrates the increasing commercial diversity of Alzheimer’s R&D, with companies exploring inflammation, autophagy, tau, metabolism and neuroprotection alongside amyloid.

New research links Alzheimer’s biology, sleep and epilepsy beginning after age 55

A study appearing in today’s issue of Neurology examined 85 people with late-onset unexplained epilepsy, with an average age of 71.3 years. Researchers combined plasma p-tau217, cognitive testing and 24-hour EEG sleep measurements.

Higher p-tau217 levels were associated with poorer cognition, particularly among people with medication-resistant epilepsy. Researchers also found disrupted coupling between sleep spindles and slow oscillations, with statistical mediation analysis suggesting that this sleep feature accounted for approximately 24% of the association between p-tau217 and cognition.

The study is small and does not establish causation, but it supports a broader move towards treating sleep, neurological events and cognitive biomarkers as interconnected elements of brain health.

Fall prevention becomes a strategy for preserving independence

The US Falls Prevention Awareness Week, running September 21–25, is placing renewed focus on the fact that falls are preventable rather than an inevitable consequence of ageing. NCOA is promoting risk assessment, exercise, medication review, vision care and home adaptation.

Recent randomized-trial evidence strengthens the case. A systematic review of perturbation-based balance training found approximately a 23% reduction in fall rates and a 24% reduction in injurious falls, with stronger results in programmes delivering at least six hours of training.

This creates opportunities far beyond physical therapy. Wearables, environmental sensors, AI gait analysis, smart homes, robotics and remote rehabilitation could make fall prevention one of AgeTech’s most important markets. Preventing the first serious fall can preserve health, independence and economic autonomy for years.

Menopause moves into public policy, workplace health and women’s longevity

More than 125 advocates from 29 US states are gathering in Washington today for the first Perimenopause & Menopause Capitol Hill Day, calling for greater investment in research and clinician education, better access to evidence-based care, insurance coverage and reimbursement, and stronger workplace support.

WHO now treats menopause through a life-course health framework and explicitly links it to healthy ageing. It also notes that unmanaged symptoms can contribute to absenteeism, lower earnings and early workforce exit.

For employers and healthcare organisations, the issue therefore extends far beyond symptom management. Women typically experience menopause between 45 and 55, often at the height of their professional experience. Women’s health, employee benefits and talent strategy are starting to converge. Earlier this month, ISO also launched ISO 45010, the first international standard offering workplace guidance on menstruation and menopause.

The key takeaway

The Longevity Economy is shifting from simply adding years to life towards preserving capability across those additional years.